Developing therapies to directly target KRAS is challenging. In The New England Journal of Medicine, Hong et al. report a promising KRAS-targeting therapy phase I trial. However, a deeper understanding of the underlying biology of each histological context might well be required to optimize the potential benefit of this class of agents.

中文翻译：

---

KRAS ^G12C难以捉摸的有效目标

开发直接针对KRAS的疗法具有挑战性。在《新英格兰医学杂志》中，Hong等人。报告了有前途的KRAS靶向治疗I期试验。但是，可能需要对每种组织学背景的基础生物学有更深入的了解，以优化此类药物的潜在利益。